Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation
- PMID: 8331574
Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation
Abstract
Oxidative metabolism of omeprazole (OPZ) was studied in 14 human liver microsomes in relation to the 4'-hydroxylation capacity of S-mephenytoin. The formation of 5-hydroxyomeprazole and omeprazole sulfone (OPZ-SFN) from OPZ exhibited a biphasic kinetic behavior, indicating that at least two distinct enzymes are involved in either of the metabolic pathways of OPZ. By using a two-enzyme kinetic approach, the activities were described by high (Km1 and Vmax1)- and low-affinity components (Km2 and Vmax2). The respective mean (+/- S.D.) kinetic parameters for 5-hydroxylation and sulfoxidation were: Km1 = 6.0 +/- 2.4 and 10.2 +/- 7.2 microM and Vmax1 = 88.0 +/- 70.2 and 66.9 +/- 53.9 pmol/mg/min; Km2 = 106 +/- 127 and 482 +/- 472 microM and Vmax2 = 116 +/- 88 and 299 +/- 131 pmol/mg/min. Among these kinetic parameters, only the Vmax1 of 5-hydroxylation gave a close correlation with the corresponding parameter of S-mephenytoin (rs = 0.911, P < .01). In addition, OPZ and S-mephenytoin inhibited competitively each other's metabolism with the respective Ki values of 2.0 and 162 microM. Interestingly, OPZ-SFN also inhibited competitively 4'-hydroxylation of S-mephenytoin with a Ki value of 8.2 microM. Moreover, polyclonal antibodies raised against S-mephenytoin 4'-hydroxylase (P450 form) partially inhibited the 5-hydroxylation of OPZ, whereas no inhibition was observed for the sulfoxidation. These findings suggest that S-mephenytoin 4'-hydroxylase is an enzyme primarily responsible for the 5-hydroxylation of OPZ and further metabolism of OPZ-SFN, but not for the sulfoxidation of OPZ in human liver microsomes.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.Br J Clin Pharmacol. 1994 Mar;37(3):237-42. doi: 10.1111/j.1365-2125.1994.tb04269.x. Br J Clin Pharmacol. 1994. PMID: 8198931 Free PMC article.
-
Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.Arch Biochem Biophys. 1998 May 1;353(1):16-28. doi: 10.1006/abbi.1998.0615. Arch Biochem Biophys. 1998. PMID: 9578596
-
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.Pharmacogenetics. 1996 Feb;6(1):81-91. doi: 10.1097/00008571-199602000-00007. Pharmacogenetics. 1996. PMID: 8845864
-
Drug interactions with proton pump inhibitors.Drug Saf. 1997 Mar;16(3):171-9. doi: 10.2165/00002018-199716030-00003. Drug Saf. 1997. PMID: 9098655 Review.
-
[The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].Sheng Li Ke Xue Jin Zhan. 1995 Jan;26(1):23-8. Sheng Li Ke Xue Jin Zhan. 1995. PMID: 7604218 Review. Chinese.
Cited by
-
A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.J Gastroenterol. 2010 Oct;45(10):1045-52. doi: 10.1007/s00535-010-0246-0. Epub 2010 Jun 12. J Gastroenterol. 2010. PMID: 20549256
-
The relationship between the bioactivation and detoxification of diazinon and chlorpyrifos, and the inhibition of acetylcholinesterase activity in Chirostoma jordani from three lakes with low to high organophosphate pesticides contamination.Ecotoxicology. 2014 Jul;23(5):779-90. doi: 10.1007/s10646-014-1216-8. Epub 2014 Feb 27. Ecotoxicology. 2014. PMID: 24573775
-
One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.Eur J Clin Pharmacol. 2015 Dec;71(12):1467-75. doi: 10.1007/s00228-015-1941-9. Epub 2015 Oct 2. Eur J Clin Pharmacol. 2015. PMID: 26427705 Clinical Trial.
-
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. doi: 10.1007/s00228-007-0302-8. Epub 2007 Jun 13. Eur J Clin Pharmacol. 2007. PMID: 17565490 Clinical Trial.
-
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. Clin Pharmacokinet. 2002. PMID: 12222994 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous